Keng-Li Lan, Associate  Professor
 
Name: Keng-Li Lan
Current position: Associate Professor
Tel:  +886-2-2875-7270  ext. 256
Fax: +886-2-2874-9425
E-mail: kllan@vghtpe.gov.tw

Education:
1985 - 1992 MD, National Yang-Ming University, Taiwan
19
94
 - 1999 PhD,
University of Michigan, USA
1999 -
2001 
Post-doctoral Researcher,University of Michigan, USA

Experiences:
2001 - 2004 Adjunct Lecturer, Molecular and Cellular Oncology, UT MD Anderson Cancer Center
2004 - 2009 R
esident Physician, Cancer Tumor Center, Taipei Veterans General Hospital
200
9 - 2013 Visiting Staff, Cancer Tumor Center, Taipei Veterans General Hospital
2008 - 2013 
Adjunct Associate Professor, Department of Biomedical Imaging and Radiological Sciences,
                       National Yamg-Ming University

2013 - 2014   Adjunct Visiting Staff, Department of Oncology, Taipei Veterans General Hospital
201
4 - now 
Associate Professor, Institute of Traditional Medicine, National Yang-Ming University

Research Interests:

  1. Pharmacologic study of targeted cancer therapy
  2. Radiation Therapy for Cancer
  3. Cancer Gene Therapy

Publications:

1.          Chang YJ, Hsu WH, Chang CH, Lan KL, Ting G, Lee TW. Combined therapeutic efficacy of Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26- murine colon cancer cells. Molecular and clinical oncology. May 2014;2(3):380-384.

2.          Lan KH, Liu YC, Shih YS, Yen SH, Lan KL. A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. Biochemical and biophysical research communications. Sep 13 2013.

3.          Liu YM, Liu YK, Lan KL, Lee YW, Tsai TH, Chen YJ. Medicinal Fungus Antrodia cinnamomea Inhibits Growth and Cancer Stem Cell Characteristics of Hepatocellular Carcinoma. Evidence-based complementary and alternative medicine : eCAM. 2013;2013:569737.

4.          Chang YJ, Hsu CW, Chang CH, Lan KL, Ting G, Lee TW. Therapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor model. Investigational new drugs. Aug 2013;31(4):801-811.

5.          Hsu CW, Chang YJ, Chang CH, et al. Comparative Therapeutic Efficacy of Rhenium-188 Radiolabeled-Liposome and 5-Fluorouracil in LS-174T Human Colon Carcinoma Solid Tumor Xenografts. Cancer biotherapy & radiopharmaceuticals. Oct 2012;27(8):481-489.

6.          Chang YJ, Hsu CW, Chang CH, Lan KL, Ting G, Lee TW. Therapeutic efficacy of (188)Re-liposome in a C26 murine colon carcinoma solid tumor model. Investigational new drugs. Dec 9 2012.

7.          Liu CM, Lee WC, Yu CY, et al. Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model. Oncology reports. Mar 2012;27(3):678-684.

8.          Lan KH, Shih YS, Chang CA, Yen SH, Lan KL. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells. Biochemical and biophysical research communications. Oct 22 2012.

9.          Lan KH, Wang YW, Lee WP, et al. Multiple effects of Honokiol on the life cycle of hepatitis C virus. Liver international : official journal of the International Association for the Study of the Liver. Jul 2012;32(6):989-997.

10.      Chen LC, Wu YH, Liu IH, et al. Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nuclear medicine and biology. Jan 2012;39(1):35-43.

11.      Tai SK, Chang HC, Lan KL, et al. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol. Mar 1 2012;188(5):2464-2471.

12.      Tsai CC, Chang CH, Chen LC, et al. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice. International journal of nanomedicine. 2011;6:2607-2619.

13.      Lan KL, Lan KH, Sheu ML, et al. Honokiol inhibits hypoxia-inducible factor-1 pathway. International journal of radiation biology. Jun 2011;87(6):579-590.

14.      Lan KL, Ou-Yang F, Yen SH, Shih HL, Lan KH. Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer. Clinical & experimental metastasis. May 2010;27(5):307-318.

15.      Lan KH, Lan KL, Lee WP, et al. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. Journal of hepatology. May 2007;46(5):759-767.

16.      Lan KL, Yen SH, Liu RS, Shih HL, Tseng FW, Lan KH. Mutant Bik gene transferred by cationic liposome inhibits peritoneal disseminated murine colon cancer. Clinical & experimental metastasis. 2007;24(6):461-470.

17.      Ou-Yang F, Lan KL, Chen CT, et al. Endostatin-cytosine deaminase fusion protein suppresses tumor growth by targeting neovascular endothelial cells. Cancer research. Jan 1 2006;66(1):378-384.

18.      Fu Y, Zhong H, Nanamori M, et al. RGS-insensitive G-protein mutations to study the role of endogenous RGS proteins. Methods in enzymology. 2004;389:229-243.

19.      Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. Jun 2003;6(3):129-136.

20.      Wade SM, Lan K, Moore DJ, Neubig RR. Inverse agonist activity at the alpha(2A)-adrenergic receptor. Molecular pharmacology. Mar 2001;59(3):532-542.

21.      Lan KL, Zhong H, Nanamori M, Neubig RR. Rapid kinetics of regulator of G-protein signaling (RGS)-mediated Galphai and Galphao deactivation. Galpha specificity of RGS4 AND RGS7. The Journal of biological chemistry. Oct 27 2000;275(43):33497-33503.

22.      Wade SM, Lim WK, Lan KL, Chung DA, Nanamori M, Neubig RR. G(i) activator region of alpha(2A)-adrenergic receptors: distinct basic residues mediate G(i) versus G(s) activation. Molecular pharmacology. Nov 1999;56(5):1005-1013.

23.      Lan KL, Remmers AE, Neubig RR. Roles of G(o)alpha tryptophans in GTP hydrolysis, GDP release, and fluorescence signals. Biochemistry. Jan 20 1998;37(3):837-843.

24.      Lan KL, Sarvazyan NA, Taussig R, et al. A point mutation in Galphao and Galphai1 blocks interaction with regulator of G protein signaling proteins. The Journal of biological chemistry. May 22 1998;273(21):12794-12797.

 

HOME